The Five-year Shareholder Returns and Company Earnings Persist Lower as Guangdong Marubi Biotechnology (SHSE:603983) Stock Falls a Further 6.2% in Past Week
The Five-year Shareholder Returns and Company Earnings Persist Lower as Guangdong Marubi Biotechnology (SHSE:603983) Stock Falls a Further 6.2% in Past Week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But even the best stock picker will only win with some selections. At this point some shareholders may be questioning their investment in Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983), since the last five years saw the share price fall 46%. Shareholders have had an even rougher run lately, with the share price down 16% in the last 90 days. Of course, this share price action may well have been influenced by the 7.4% decline in the broader market, throughout the period.
爲了證明選擇個股的努力是合理的,值得努力超過市場指數基金的回報。但是,即使是最好的選股者也只能通過某些選擇獲勝。目前,一些股東可能會質疑他們對廣東丸美生物技術有限公司(SHSE: 603983)的投資,因爲在過去五年中,股價下跌了46%。股東們最近的表現更加艱難,股價在過去90天中下跌了16%。當然,這種股價走勢很可能受到了整個時期大盤下跌7.4%的影響。
After losing 6.2% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.
在上週下跌6.2%之後,值得研究該公司的基本面,看看我們可以從過去的表現中推斷出什麼。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
用本傑明·格雷厄姆的話來說:從短期來看,市場是一臺投票機器,但從長遠來看,它是一臺稱重機。考慮市場對公司的看法發生了怎樣的變化的一種不完美但簡單的方法是將每股收益(EPS)的變化與股價走勢進行比較。
Looking back five years, both Guangdong Marubi Biotechnology's share price and EPS declined; the latter at a rate of 9.7% per year. Notably, the share price has fallen at 12% per year, fairly close to the change in the EPS. This implies that the market has had a fairly steady view of the stock. Rather, the share price has approximately tracked EPS growth.
回顧五年,廣東丸美生物科技的股價和每股收益均有所下降;後者每年下降9.7%。值得注意的是,股價每年下跌12%,與每股收益的變化非常接近。這意味着市場對該股的看法相當穩定。相反,股價大致追蹤了每股收益的增長。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240725/0-f6ed560cad689723052d82532a002615-0-c84f8320f5f3155a0d6b3b48486be618.png/big)
We know that Guangdong Marubi Biotechnology has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Guangdong Marubi Biotechnology will grow revenue in the future.
我們知道廣東丸美生物科技最近提高了利潤,但它會增加收入嗎?看看分析師是否認爲廣東丸美生物科技未來會增加收入。
What About Dividends?
分紅呢?
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Guangdong Marubi Biotechnology's TSR for the last 5 years was -43%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!
在考慮投資回報時,重要的是要考慮股東總回報(TSR)和股價回報之間的差異。股東總回報率是一種回報計算方法,它考慮了現金分紅的價值(假設收到的任何股息都經過再投資)以及任何貼現資本籌集和分拆的計算價值。因此,對於支付豐厚股息的公司來說,股東總回報率通常遠高於股價回報率。碰巧的是,廣東丸美生物科技過去5年的股東總回報率爲-43%,超過了前面提到的股價回報率。這在很大程度上是其股息支付的結果!
A Different Perspective
不同的視角
The total return of 19% received by Guangdong Marubi Biotechnology shareholders over the last year isn't far from the market return of -19%. So last year was actually even worse than the last five years, which cost shareholders 7% per year. It will probably take a substantial improvement in the fundamental performance for the company to reverse this trend. It's always interesting to track share price performance over the longer term. But to understand Guangdong Marubi Biotechnology better, we need to consider many other factors. To that end, you should be aware of the 2 warning signs we've spotted with Guangdong Marubi Biotechnology .
去年,廣東丸美生物科技股東獲得的總回報率爲19%,與-19%的市場回報率相差不遠。因此,去年的情況實際上比過去五年還要糟糕,後者每年使股東損失7%。要扭轉這一趨勢,該公司的基本業績可能需要大幅改善。長期跟蹤股價表現總是很有意思的。但是,要更好地了解廣東丸美生物科技,我們需要考慮許多其他因素。爲此,你應該注意我們在廣東丸美生物技術中發現的兩個警告信號。
If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.
如果你像我一樣,那麼你一定不想錯過這份內部人士正在買入的被低估的小盤股的免費清單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件至 editorial-team@simplywallst.com